← ANALYST RATINGS · TIPRANKS
Aura Biosciences Inc (AURA): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $20.50, the highest $23.00, the lowest $18.00. The average is +236.1% from the last price of $6.10.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $6.00−7.7% | Hold | −1.6% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $6.00−7.7% | Hold | −1.6% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.50 → $6.00−7.7% | Hold | −1.6% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.00 → $6.50−7.1% | Hold | +6.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $6.00−7.7% | Hold | −1.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 → $6.00+9.1% | Sell | −1.6% | Downgrade | 29.09.26on TipRanks 06:05 | — | |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $23.00 | Buy | +277.0% | Reiterated | 12.08.26on TipRanks 16:45 | −2.0%next day +0.7% · 5 days +3.5% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $24.00 → $18.00−25.0% | Buy | +195.1% | Reiterated | 12.08.26on TipRanks Aug 11 11:34 | +4.7%next day −3.9% · 5 days +1.9% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | — | Buy | — | Reiterated | 02.06.26on TipRanks Jun 4 22:20 | −4.2%next day +0.4% · 5 days −5.0% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 11.05.26on TipRanks 18:35 | −3.0%next day +0.6% · 5 days −6.2% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $13.00 → $15.00+15.4% | Buy | +145.9% | Reiterated | 13.04.26on TipRanks 09:50 | +0.6%next day +1.4% · 5 days −1.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Aura Biosciences Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.50 at a price of $6.28 (+226.4%); now: $20.50 at $6.10 (+236.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 7 | 6 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.37 (from $-0.41 to $-0.32). Last quarter: $-0.48.
Best top-analyst consensus in the sector · Healthcare
About Aura Biosciences Inc
- CEO: Natalie C. Holles
- Employees: 113
- 85 Bolton Street, Boston, MA, 02135, US
- www.aurabiosciences.com
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Data from the stock’s TipRanks forecast page, read 198 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗